TGA Schedule 4 + research peptides — what Australian researchers can buy

The TGA was established under the Therapeutic Goods Act 1989 to regulate medicines, medical devices, and biologicals in Australia. The SUSMP places compounds into 10 schedules based on their toxicity and risk profile. Schedule 4 is the prescription-only category — compounds that require a registered medical practitioner's prescription for legal possession or supply. The schedule applies regardless of intent: a Schedule 4 substance imported for "personal research" without a prescription is in violation if the substance was supplied as a therapeutic good.

Research peptides occupy an awkward position. The active molecules — BPC-157, TB-500, GHK-Cu, Selank, Semax — are mostly not approved as therapeutic goods in Australia (none have ARTG registration). They are sold internationally as research chemicals with research-use-only labels. The TGA position is that research-use-only labelling does NOT exempt a substance from Schedule 4 if the substance has a known therapeutic application. The Poisons Standard names BPC-157, TB-500, ipamorelin, CJC-1295 and AOD-9604 in Schedule 4 and in Appendix D, clause 5 (poisons that must not be possessed without authority, for example other than under a legal prescription), whatever the label says. GHK-Cu, Selank and Semax are not named in it.

The Customs Act 1901 is the second layer. Section 233BAA makes importing "tier 1 goods" without the required permission an offence. Tier 1 goods include growth hormones, insulin-like growth factors and growth hormone releasing hormones and their synthetic analogues, which the Customs (Prohibited Imports) Regulations 1956 (Schedule 7A) prohibit importing without written permission from the Department of Health, Disability and Ageing. Schedule 4 status on its own does not make a peptide a tier 1 good. Australian Border Force (ABF) screens international shipments and intercepts packages identified as containing therapeutic-use compounds. PeptideGuide has no figures on how often research-peptide parcels from any origin are intercepted; 1 of the 4 tracked AU vendors carries an explicit warning that TGA Schedule 4 controls apply and research-use-only labelling does not exempt shipments.

The TGA Personal Importation Scheme (PIS) is sometimes cited as a path. It lets individuals import unapproved therapeutic goods for their own or an immediate family member's use, up to a 3-month supply, but a prescription-only medicine needs a valid Australian prescription or written authority held at the time of import. Controlled substances and goods prohibited under Customs rules cannot be imported under the scheme. There is no separate TGA personal importation permit.

The Special Access Scheme (SAS) and the Authorised Prescriber scheme are sometimes described as institutional research routes. They are not: both let registered health practitioners access unapproved therapeutic goods to treat patients, the SAS for an individual patient on a case-by-case basis. Neither covers buying peptides for laboratory research.

Vendors ship to Australia anyway, but that does not make the import lawful. For the peptides named in Appendix D, clause 5 of the Poisons Standard, possession without authority is illegal, and TGA says imports that do not meet the Personal Importation Scheme conditions may be seized and destroyed, with fines or civil or criminal proceedings possible (TGA). PeptideGuide has no data on how often individual buyers are prosecuted.

The 3 AU-shipping vendors PeptideGuide currently tracks (Pharma Lab Global, SwissChems, Pepsup) all maintain research-use-only labelling. One (Pharma Lab Global) carries a warning flag on the vendor record that TGA Schedule 4 controls apply and research-use-only labelling does not exempt shipments; SwissChems lists the same TGA constraint among its cons. The full vendor reviews flag the customs reality and let researchers self-screen.

More from this region.

Other articles covering this region's vendors, regulatory framework, and research peptides.

• 2026-10-31Earlier versions counted 4 tracked AU-shipping vendors, listed QSC Peptides (removed in October 2026 after its store went offline) among them, and said two tracked vendors carry TGA import warnings. 3 vendors are tracked and one (Pharma Lab Global) carries the warning flag.
• 2026-10-12Earlier versions said research-use-only labelling places peptides outside Schedule 4, that Schedule 4 applies only when peptides are used therapeutically, that laboratory use keeps buyers "below the TGA radar", that the Personal Importation Scheme requires a product registered elsewhere, that the Special Access Scheme and Authorised Prescriber scheme are routes for institutional research (with SAS Category C described as emergency use), that Schedule 4 listing makes peptides prohibited imports under Customs Act s233BAA, and that personal buyers are in a "grey zone" mainly policed by the ACCC. The October 2026 Poisons Standard lists BPC-157, TB-500 and other research peptides in Schedule 4 and Appendix D, clause 5 (possession without authority is illegal); TGA describes the SAS as patient access through a health practitioner; and s233BAA applies to tier 1 goods such as growth hormones and IGFs. The text was corrected with links to TGA and legislation.gov.au.
• 2026-10-08Earlier versions said UK-origin parcels fare better at Australian customs than US-origin, which fare better than China-origin, and that the operator had verified interception rates for flagged vendors. PeptideGuide holds no interception data; the two flagged vendors are the UK-origin ones, and their flags concern TGA Schedule 4 import status. The text was corrected.